Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia

Robert (Rob) Bennett, David M. Cook, Sharon R. Clark, Carol S. Burckhardt, Stephen M. Campbell

    Research output: Contribution to journalArticle

    140 Citations (Scopus)

    Abstract

    Objective. To investigate the serum levels of insulin-like growth factor-I (IGF-1) in patients with fibromyalgia (FM) compared to healthy controls and patients with other rheumatic diseases, and to explore possible etiologic mechanisms of low IGF-I levels in patients with FM. Methods. Five hundred patients with FM and 152 controls (74 healthy blood donors, 26 myofascial pain patients and 52 patients with other rheumatic diseases) were studied. All had measurements of acid extracted serum IGF-I. A subset of 90 patients with FM were evaluated for clinical features that might explain low IGF4-1 levels. Twenty-five patients with FM underwent growth hormone (GH) provocation testing with l-dopa and clonidine. Results. The mean serum IGF-I level in patients with FM was 138 ± 56 ng/ml and in controls 215 ± 86 ng/ml (p = 0.00000000001). Low levels of IGF-I were not due to depression, tricyclic medications, nonsteroidal antiinflammatory drugs, poor aerobic conditioning, obesity, or pain level. Patients with focal myofascial pain syndromes had normal IGF-I levels (236 ± 68), as did most patients with other rheumatic disorders, unless they had concomitant FM. Patients with FM with initially normal levels often had a rapid decline of IGF-I over 1 to 2 years. Most patients with FM with low IGF-I levels failed to secrete GH after stimulation with clonidine and I-dopa. Conclusion. Many, but not all, patients with FM have low levels of IGF-I that cannot be explained by clinical associations. These results suggest that low [GF-I levels in patients with FM are a secondary phenomenon due to hypothalamic-pituitary GH axis dysfunction.

    Original languageEnglish (US)
    Pages (from-to)1384-1389
    Number of pages6
    JournalJournal of Rheumatology
    Volume24
    Issue number7
    StatePublished - Jul 1997

    Fingerprint

    Fibromyalgia
    Insulin-Like Growth Factor I
    Growth Hormone
    Dihydroxyphenylalanine
    Clonidine
    Rheumatic Diseases
    Serum
    Myofascial Pain Syndromes
    Pain
    Blood Donors

    Keywords

    • Deficiency
    • Fibromyalgia
    • Growth hormone
    • Insulin-like growth factor- I
    • Myofascial pain

    ASJC Scopus subject areas

    • Rheumatology
    • Immunology

    Cite this

    Bennett, R. R., Cook, D. M., Clark, S. R., Burckhardt, C. S., & Campbell, S. M. (1997). Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. Journal of Rheumatology, 24(7), 1384-1389.

    Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. / Bennett, Robert (Rob); Cook, David M.; Clark, Sharon R.; Burckhardt, Carol S.; Campbell, Stephen M.

    In: Journal of Rheumatology, Vol. 24, No. 7, 07.1997, p. 1384-1389.

    Research output: Contribution to journalArticle

    Bennett, RR, Cook, DM, Clark, SR, Burckhardt, CS & Campbell, SM 1997, 'Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia', Journal of Rheumatology, vol. 24, no. 7, pp. 1384-1389.
    Bennett RR, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. Journal of Rheumatology. 1997 Jul;24(7):1384-1389.
    Bennett, Robert (Rob) ; Cook, David M. ; Clark, Sharon R. ; Burckhardt, Carol S. ; Campbell, Stephen M. / Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. In: Journal of Rheumatology. 1997 ; Vol. 24, No. 7. pp. 1384-1389.
    @article{28feccd452444a94baff6ae11e41672f,
    title = "Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia",
    abstract = "Objective. To investigate the serum levels of insulin-like growth factor-I (IGF-1) in patients with fibromyalgia (FM) compared to healthy controls and patients with other rheumatic diseases, and to explore possible etiologic mechanisms of low IGF-I levels in patients with FM. Methods. Five hundred patients with FM and 152 controls (74 healthy blood donors, 26 myofascial pain patients and 52 patients with other rheumatic diseases) were studied. All had measurements of acid extracted serum IGF-I. A subset of 90 patients with FM were evaluated for clinical features that might explain low IGF4-1 levels. Twenty-five patients with FM underwent growth hormone (GH) provocation testing with l-dopa and clonidine. Results. The mean serum IGF-I level in patients with FM was 138 ± 56 ng/ml and in controls 215 ± 86 ng/ml (p = 0.00000000001). Low levels of IGF-I were not due to depression, tricyclic medications, nonsteroidal antiinflammatory drugs, poor aerobic conditioning, obesity, or pain level. Patients with focal myofascial pain syndromes had normal IGF-I levels (236 ± 68), as did most patients with other rheumatic disorders, unless they had concomitant FM. Patients with FM with initially normal levels often had a rapid decline of IGF-I over 1 to 2 years. Most patients with FM with low IGF-I levels failed to secrete GH after stimulation with clonidine and I-dopa. Conclusion. Many, but not all, patients with FM have low levels of IGF-I that cannot be explained by clinical associations. These results suggest that low [GF-I levels in patients with FM are a secondary phenomenon due to hypothalamic-pituitary GH axis dysfunction.",
    keywords = "Deficiency, Fibromyalgia, Growth hormone, Insulin-like growth factor- I, Myofascial pain",
    author = "Bennett, {Robert (Rob)} and Cook, {David M.} and Clark, {Sharon R.} and Burckhardt, {Carol S.} and Campbell, {Stephen M.}",
    year = "1997",
    month = "7",
    language = "English (US)",
    volume = "24",
    pages = "1384--1389",
    journal = "Journal of Rheumatology",
    issn = "0315-162X",
    publisher = "Journal of Rheumatology",
    number = "7",

    }

    TY - JOUR

    T1 - Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia

    AU - Bennett, Robert (Rob)

    AU - Cook, David M.

    AU - Clark, Sharon R.

    AU - Burckhardt, Carol S.

    AU - Campbell, Stephen M.

    PY - 1997/7

    Y1 - 1997/7

    N2 - Objective. To investigate the serum levels of insulin-like growth factor-I (IGF-1) in patients with fibromyalgia (FM) compared to healthy controls and patients with other rheumatic diseases, and to explore possible etiologic mechanisms of low IGF-I levels in patients with FM. Methods. Five hundred patients with FM and 152 controls (74 healthy blood donors, 26 myofascial pain patients and 52 patients with other rheumatic diseases) were studied. All had measurements of acid extracted serum IGF-I. A subset of 90 patients with FM were evaluated for clinical features that might explain low IGF4-1 levels. Twenty-five patients with FM underwent growth hormone (GH) provocation testing with l-dopa and clonidine. Results. The mean serum IGF-I level in patients with FM was 138 ± 56 ng/ml and in controls 215 ± 86 ng/ml (p = 0.00000000001). Low levels of IGF-I were not due to depression, tricyclic medications, nonsteroidal antiinflammatory drugs, poor aerobic conditioning, obesity, or pain level. Patients with focal myofascial pain syndromes had normal IGF-I levels (236 ± 68), as did most patients with other rheumatic disorders, unless they had concomitant FM. Patients with FM with initially normal levels often had a rapid decline of IGF-I over 1 to 2 years. Most patients with FM with low IGF-I levels failed to secrete GH after stimulation with clonidine and I-dopa. Conclusion. Many, but not all, patients with FM have low levels of IGF-I that cannot be explained by clinical associations. These results suggest that low [GF-I levels in patients with FM are a secondary phenomenon due to hypothalamic-pituitary GH axis dysfunction.

    AB - Objective. To investigate the serum levels of insulin-like growth factor-I (IGF-1) in patients with fibromyalgia (FM) compared to healthy controls and patients with other rheumatic diseases, and to explore possible etiologic mechanisms of low IGF-I levels in patients with FM. Methods. Five hundred patients with FM and 152 controls (74 healthy blood donors, 26 myofascial pain patients and 52 patients with other rheumatic diseases) were studied. All had measurements of acid extracted serum IGF-I. A subset of 90 patients with FM were evaluated for clinical features that might explain low IGF4-1 levels. Twenty-five patients with FM underwent growth hormone (GH) provocation testing with l-dopa and clonidine. Results. The mean serum IGF-I level in patients with FM was 138 ± 56 ng/ml and in controls 215 ± 86 ng/ml (p = 0.00000000001). Low levels of IGF-I were not due to depression, tricyclic medications, nonsteroidal antiinflammatory drugs, poor aerobic conditioning, obesity, or pain level. Patients with focal myofascial pain syndromes had normal IGF-I levels (236 ± 68), as did most patients with other rheumatic disorders, unless they had concomitant FM. Patients with FM with initially normal levels often had a rapid decline of IGF-I over 1 to 2 years. Most patients with FM with low IGF-I levels failed to secrete GH after stimulation with clonidine and I-dopa. Conclusion. Many, but not all, patients with FM have low levels of IGF-I that cannot be explained by clinical associations. These results suggest that low [GF-I levels in patients with FM are a secondary phenomenon due to hypothalamic-pituitary GH axis dysfunction.

    KW - Deficiency

    KW - Fibromyalgia

    KW - Growth hormone

    KW - Insulin-like growth factor- I

    KW - Myofascial pain

    UR - http://www.scopus.com/inward/record.url?scp=0030839072&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0030839072&partnerID=8YFLogxK

    M3 - Article

    C2 - 9228141

    AN - SCOPUS:0030839072

    VL - 24

    SP - 1384

    EP - 1389

    JO - Journal of Rheumatology

    JF - Journal of Rheumatology

    SN - 0315-162X

    IS - 7

    ER -